CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Deutsche Biotech Innovativ AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Deutsche Biotech Innovativ AG
Neuendorfstrasse 15a
Phone: +49 33022077824p:+49 33022077824 HENNIGSDORF, 16761  Germany Ticker: DBIDBI
Business Summary
Deutsche Biotech Innovativ AG, formerly, Venetus Beteiligungen AG, is a Germany-based biotechnology company. The Company focuses on the identification of relevant biomarkers in the blood of affected patients and develops targeted therapies to prevent septic shock and inhibit tumour growth, as well as a small molecule drug for breast cancer prevention, Procizumab, focus on antibody-based therapy for the treatment of organ failure in patients with cardiogenic shock. Its product portfolio comprises various indicators, among others, for sepsis therapy (Adrecizumab), for breast cancer prevention (DB1RA) and for cancer therapy (AB2302). Its research and development activities are entirely conducted by project companies, in which the Company holds interest.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
6799 Investors, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Supervisory Board RenkeLuehrs 62 2/15/2011 2/15/2011
Deputy Chairman of the Supervisory Board MetodMiklus 63 10/7/2019 9/8/2016
Member of the Management Board AndreasBergmann 61 1/1/2017 12/9/2010
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Adrenomed AG
DBI

General Information
Outstanding Shares: 947,296 (As of 12/31/2023)
Stock Exchange: FRA
Fax Number: +49 33022077815
Email Address: info@dbi-ag.de


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024